Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.7 NOK | -12.13% | +2.06% | +19.76% |
03-05 | Transcript : Nordhealth AS, Q4 2023 Earnings Call, Mar 05, 2024 | |
03-05 | Nordhealth AS Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 51.69 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.76% | 242M | - | ||
+4.71% | 32.47B | C | ||
+15.79% | 7.45B | C- | ||
+23.49% | 3.89B | B- | ||
-15.80% | 3.17B | C- | ||
-27.19% | 1.28B | B | ||
-33.58% | 1.09B | - | ||
-33.74% | 902M | - | ||
+1.56% | 893M | C | ||
-23.93% | 857M | - | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NORDH Stock
- Ratings Nordhealth